The Fourth of July fireworks may be over, but sparks are still sizzling (along with the weather) here at the Research Institute as we celebrate our researchers’ published work. Take a look at who’s been in the press lately. This week we’re covering the decision factors behind allowing children to ride alone in self-driving cars, commentary on improving perinatal care in the United States, and why private sector working families are turning to Medicaid and CHIP for health coverage.
Tag Archive: Adam Resnick
By Jillian Rose Lim, Barbara Drosey, Sharlene George, and Nancy McCann
Researchers exchanged big ideas about big data at the 2019 Scientific Symposium, an event that brought together the bright minds of our Children’s Hospital of Philadelphia research community. A lineup of thought-provoking speakers from CHOP and the University of Pennsylvania shared presentations corresponding with the symposium’s themes, “Big Data” and “Today’s Discoveries and Tomorrow’s Possibilities.”
“The goal [of this symposium] is to highlight the tremendous advances by CHOP investigators in the booming fields of computational biology, data science, and genomics,” said Yi Xing, PhD, chair of the event and director of the Center for Computational and Genomic Medicine at CHOP.
Fall weather and football season have returned to us here at Children’s Hospital of Philadelphia Research Institute, bringing with them a fresh batch of research headlines. In this edition of our biweekly news roundup, catch up on the latest announcements for the second annual Eagles Autism Challenge, learn about new insights into the role mitochondrial DNA plays in heart disease progression, and stay updated on how CHOP helps to drive medical innovation and entrepreneurship forward in the Philadelphia community and beyond.
When most of us think about cancer, a number of factors — from smoking, to sun exposure, to specific organs where a disorder develops — might jump to mind. But for Adam Resnick, PhD, co-founder of the Center for Data Driven Discovery and Biomedicine (D3B) at CHOP, in order to unravel the inextricable link between childhood cancer and other rare conditions, we must visualize pediatric cancer as a process.
As a single-cell zygote proliferates into a 37 trillion-cell being, something happens in the course of its development — a dysfunction, a deviance, a DNA-driven decision — that underpins not just the development of life-changing birth defects, but a potential vulnerability to childhood cancer as well.
Debbie Eaise remembers the day her 18-year-old son, Kevin, walked onto the University of Pennsylvania campus where he is set to play for the Penn Quakers baseball team this fall. From Meiklejohn Stadium, Penn’s home field, you can pitch a baseball and reach Children’s Hospital of Philadelphia, said Debbie — a proximity so palpable that she could see the change in her son’s face and sense his comfort level at ease while he toured his future school.
As her husband, Kevin Sr., and others have noted, Kevin has come full circle. It was right there on the Penn-CHOP campus, after all, with its skyline of medical buildings, that Kevin and his family’s life changed inextricably, ushering in what Debbie describes as their “new normal.”
Editor’s Note: Childhood brain tumors remain some of the most difficult to treat cancers, especially because of current therapies’ long-term side effects for the survivors. In honor of Brain Tumor Awareness Month, Adam Resnick, PhD, director of the Center for Data-Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia, is our guest blogger. He brings us up to date on how the CHOP-led consortia, working with patients, families, and partnering institutions, has witnessed first-in-kind initiatives and innovative clinical trials aimed at personalized, precision-based approaches for brain tumors that are redefining the scientific landscape of research and therapeutic translation.
Editor’s Note: Families facing a rare disease diagnosis often do not know where to turn first in their search for the most advanced treatments and potentially a cure for their children. Only 5 percent of rare diseases have a treatment approved by the Food and Drug Administration, according to the National Organization for Rare Disorders. This is due in part to the lack of high quality biospecimens for research.
As the November chill settles in, warm up to new scientific discoveries and novel projects for improving children’s health from our researchers at Children’s Hospital of Philadelphia. In our roundup of research headlines, we share the latest findings on the biology of pediatric low-grade gliomas – the most common childhood brain tumor – congratulate Christopher Forrest, MD, in his role as co-investigator of a new FDA-funded clinical trials network, and give you the highlights on two new papers from researchers in mitochondrial medicine and cardiology.
Onwards and upwards: Last week’s grand opening of the new Roberts Center for Pediatric Research coincided with a series of exciting news that suggest breakthroughs are on the horizon.
Buckle your seatbelts because this has been a busy week for research news at Children’s Hospital of Philadelphia.